An open-label, single-center and single-arm clinical study for infusion of anti-CD22 CAR-T cells for patients with relapsed or refractory B-cell malignancies
Latest Information Update: 27 Jun 2019
At a glance
- Drugs Anti-CD22-chimeric-antigen-receptor-T-cell-therapies-Wuhan-Bio-Raid-Biotechnology (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- 27 Jun 2019 New trial record